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Cutaneous leishmaniasis
The Review by Richard Reithinger and colleagues1 
on cutaneous leishmaniasis was a useful update on a 
neglected but important disease.2 We would like to make 
a few comments regarding the treatment section of that 
article.
Table 2 of the Review1 provides a summary of the 
recommended and alternative treatment regimens for 
cutaneous leishmaniasis. The authors mention that with 
the exception of studies assessing treatment options 
for mucosal leishmaniasis, they only included studies in 
which monotherapies were assessed.1 There are, however, 
trials in which outcomes of monotherapy were assessed 
that are not included in the table.3–7 In these trials, 
photodynamic therapy, carbon dioxide laser, rifampicin, 
and topical ethanolic lipid amphotericin B were 
reported to be eﬀ ective in the treatment of cutaneous 
leishmaniasis, whereas oral allopurinol was not 
eﬀ ective.3–7 Additionally, there are several trials that have 
assessed the eﬃ  cacy of combination therapies in the 
treatment of cutaneous leishmaniasis.8–10 The rationale 
behind Reithinger and colleagues’ decision is required to 
explain the potential selection bias in their Review.
In the fourth column of table 2,1 clinical eﬃ  cacy against 
Leishmania spp has not been presented in a manner that 
can be clearly understood. We believe that more detailed 
description of the included studies and provision of 
95% CIs might be a better option. Example of such 
presentation is available elsewhere.11 The provided 
range for some interventions is too wide to be clinically 
meaningful without further explanation.
Finally, we noticed that despite the eﬀ orts of the 
authors to pay particular attention to articles published 
in non-English literature, several studies that where 
done in Iran might have been overlooked.12,13 The results 
of these studies are published in Persian, their English 
abstracts are available in the Cochrane Library, and 
according to the authors’ selection criteria, they appear 
to be eligible for inclusion.
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Authors’ reply 
We thank Alireza Khatami and colleagues for pointing 
out that we inadvertently missed some studies 
investigating various treatment approaches of 
cutaneous leishmaniasis in our recent Review of the 
disease.1 Indeed, the studies referred to by Khatami 
and colleagues demonstrate the wealth of clinical 
trials that have been done in Iran, many of which 
may not be familiar to researchers and practitioners 
working on cutaneous leishmaniasis. Thus, according 
to the criteria set out in our Review,1 we should have 
included a study from Iran that presents efficacy data 
on photodynamic therapy and topical paromomycin 
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for the treatment of cutaneous leishmaniasis caused 
by Leishmania major.2
Khatami and colleagues’ critique also shows that—as 
highlighted in our Review and in a consultative meeting 
on cutaneous leishmaniasis1,3—standard criteria for 
leishmaniasis clinical trials are urgently needed. Six of 
the seven studies4–9 that the authors state should have 
been included have methodological limitations. First, 
one study had a smaller sample size than the amount 
stated as suﬃ  cient for inclusion in our Review—ie, ten 
patients per treatment cohort.6 Second, studies were 
non-randomised or did not have inclusion/exclusion 
criteria.5,6,8 Third, although these studies included a 
placebo or pentavalent antimony control arm, those 
that used a pentavalent antimony control arm used 
non-standard doses or regimens (eg, 50 mg/kg per day 
meglumine antimonate for 15 days, repeated after a 
15-day window where no treatment was given).4 Fourth, 
the parasite species causing disease in individuals enrolled 
in the trials were not identiﬁ ed.4,5 Fifth, follow-up was 
less than 2 months post treatment, making it diﬃ  cult 
for comprehensive comparison between the treatment 
arms,5,7,9 or follow-up was not speciﬁ ed.6 Finally, criteria of 
cure diﬀ ered between studies, with cure being deﬁ ned as 
either “complete re-epithelialisation and parasitological 
cure”, “complete cure”, or lesion improvement with 
“reduction of lesion size by at least 80%”.4–9 
We agree with Khatami and colleagues that research 
on combination therapies for cutaneous leishmaniasis 
should be expanded to improve eﬃ  cacy and patient 
compliance, decrease treatment cost, and delay the 
potential development of drug resistance. We decided 
to exclude combination therapies from our Review 
largely because the methodological protocols of 
studies assessing combination therapies are even less 
standardised than protocols for monotherapy trials, 
making study comparison virtually impossible.
The studies included in our Review provide a wide 
range of cure rates for diﬀ erent treatment approaches. 
However, this shows that, besides a few (recommended) 
approaches, “one size does not ﬁ t all” for cutaneous 
leishmaniasis treatment. Eﬃ  cacy of treatment is 
dependent on several factors—eg, lesion location, size, 
number, and duration—again, highlighting the need for 
standardised study protocols to exclude as far as possible 
such confounding factors from data analysis. Inclusion of 
95% CIs would not have changed our recommendations 
of ﬁ rst-line and alternative treatment approaches for 
cutaneous leishmaniasis.1
A meta-analysis on cutaneous leishmaniasis treatment 
interventions could—depending on the analyses done—
make the best use of existing clinical trial data and yield 
evidence-based treatment recommendations. However, 
even meta-analyses can only address some of the above-
mentioned methodological deﬁ ciencies to compare 
data on various approaches for cutaneous leishmaniasis 
treatment. Without developing standardised cutaneous 
leishmaniasis clinical trial criteria in the near future, 
comparisons between clinical studies will be of little 
value and no real measurable progress in treatment will 
be made.
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